We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microcytosis Is a Risk Marker of Cancer in Primary Care

By LabMedica International staff writers
Posted on 20 May 2020
Microcytosis is a term used to describe red blood cells that are smaller than normal. More...
Anemia is when there are low numbers of properly functioning red blood cells in the body. In microcytic anemia, the body has fewer red blood cells than normal and those red blood cells it does have are also too small.

In anemia of chronic disease, about one-fourth to one-third of these types of anemia are classified as microcytic. Some of the conditions that can cause this type of anemia include: kidney disease, certain cancers, such as Hodgkin's disease, non-Hodgkin's lymphoma, and breast cancer.

A team of medical scientists from the University of Exeter Medical School (Exeter, UK) examined cancer incidence in a cohort of patients with microcytosis, with and without accompanying anemia. The cohort of 12,289 patents were aged ≥40 years using UK primary care electronic patient records. The 1-year cancer incidence was compared between cohorts of patients with a mean red cell volume of <85 femtolitres (fL) (low) or 85–101 fL (normal). Further analyses examined sex, age group, cancer site, and hemoglobin values.

The investigators reported that of 12,289 patients with microcytosis, 497 (4.0%) had a new cancer diagnosis within one year, compared with 1,465 of 73,150 (2.0%), without microcytosis. In males, 298 out of 4,800 with microcytosis were diagnosed with cancer (6.2%) compared with 940 out of 34,653 without (2.7%). In females with microcytosis, 199 out of 7,489 were diagnosed with cancer (2.7%), compared with 525 out of 38 497 without (1.4%). In patients with microcytosis but normal hemoglobin, 86 out of 2,637 males (3.3%), and 101 out of 5,055 females (2.0%) were diagnosed with cancer.

Willie Hamilton, MD, a Professor of Primary Care Diagnostics who oversaw the study, said, “Overall, the risk of cancer in patients with microcytosis was still low, however our study indicates a need to investigate cancer. In two patients with cancer out of three the possibility of cancer is fairly easy to identify. For the other third, symptoms are often vague, and don't clearly point to cancer. For these patients physicians have to use more subtle clues to recognize that cancer may be present. Small red cells have long been recognized with colon cancer, but this study shows that they are a much broader clue, alerting the doctor to the small possibility of one of several possible cancers.”

The authors concluded that microcytosis is a predictor of underlying cancer even if hemoglobin is normal. Although a benign explanation is more likely, clinicians in primary care should consider simple testing for cancer on encountering unexplained microcytosis, particularly in males. The study was published on May 4, 2020 in the British Journal of General Practice.

Related Links:
University of Exeter Medical School


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The two new tests are used with the LightCycler 480 and LightCycler PRO instruments (Photo courtesy of Roche)

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance

Cyclospora cayetanensis, a food- and waterborne intestinal parasite, can cause prolonged diarrhea, fatigue, and abdominal cramping, placing added strain on urgent care and emergency departments during outbreaks.... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.